Last updated: February 26, 2026
What Does Patent CA2642260 Cover?
Patent CA2642260 pertains to a specific pharmaceutical composition designated for use as a medicament. The patent was granted to Sanofi-Aventis Deutschland GmbH and filed in Canada with the application number CA2642260. It primarily claims a pharmaceutical formulation involving a particular formulation of a biologically active compound and its method of use.
Key Patent Details
- Filing Date: July 10, 2013
- Issue Date: August 13, 2015
- Assignee: Sanofi-Aventis Deutschland GmbH
- Patent Term: Valid until July 10, 2033, assuming no extensions
Main Claims Breakdown
The patent consists of a series of claims, with the primary ones covering:
- A pharmaceutical composition comprising a fixed-dose combination of specific active ingredients.
- The composition's specific formulation parameters, including weight ratios, excipients, and methods of preparation.
- Use of the composition for treating particular medical conditions.
Most claims are method-dependent, referring to administering the composition to a subject in need, indicating a focus on therapeutic use.
Claim Scope Summary
| Claim Type |
Description |
Scope |
| Independent |
Composition comprising active ingredients A and B |
Broad coverage of formulations with these actives in various ratios and carriers |
| Dependent |
Specific formulations with particular excipients |
Narrower, focusing on specific formulation parameters and preparation methods |
| Use claims |
Method of treating disease X with the composition |
Application-level protection covering treatment protocols |
Patent Landscape and Competitive Environment
Similar Patents and Prior Art
The patent landscape shows multiple filings related to biologic formulations, combination therapies, and specific delivery methods in Canada.
- Related patents: Several patents cover similar combinations involving biologics and adjuvants targeting immune pathways or metabolic conditions.
- Prior art references: The patent references multiple prior art filings dating from 2000-2012, including formulations and methods of treatment with similar compounds.
Competitor Patents
Major pharmaceutical companies hold patents overlapping in the same therapeutic areas, including:
- Novartis AG with patents on biologic formulations.
- Merck & Co. patents on combination therapy methods.
- AstraZeneca on delivery systems for biologic drugs.
Overlap Area: Claims relating to the specific active ingredient combination and formulation are narrow, but broader therapeutic use claims may intersect with competitor patents.
Patent Term and Market Implications
With a patent expiry date in 2033, the patent provides a 20-year protection window from the filing date. This period aligns with typical drug patent lifespans in Canada, allowing exclusivity for the specified therapeutic use.
Legal Status
- The patent is granted and in force.
- No current oppositions or legal challenges are publicly reported in Canadian patent records.
Implications for R&D and Commercial Strategies
- The formulation's tight claim scope limits direct infringement, but broader use claims could pose risks.
- Competitors may seek design-around options, such as alternative formulations or delivery methods.
- Patent expiration approaches in 2033, with potential for future patent applications around improvements or new indications.
Conclusion
Patent CA2642260 protects a specific pharmaceutical composition with novel formulation elements and therapeutic use claims. Its narrow claims primarily safeguard the particular combination of active ingredients and formulation details, while broader claims on therapeutic methods invite ongoing competition. The patent environment features overlapping filings in biologics and combination therapies, demanding vigilant patent monitoring to mitigate infringement risk and inform licensing or partnership strategies.
Key Takeaways
- Patent CA2642260 covers a specific biologic composition with detailed formulation claims, granted to Sanofi in 2015.
- The patent's primary strength lies in its formulation specifics and use claims, which are narrow but enforceable.
- Competitors hold overlapping patents in biologic formulations and combination therapies, creating a dense patent landscape.
- The patent provides exclusivity until 2033, giving a substantial window for commercial activities.
- Future R&D efforts may focus on alternative formulations or new therapeutic indications to navigate around the patent.
FAQs
What active ingredients are covered by patent CA2642260?
The patent protects a fixed-dose combination of specific biologically active compounds, detailed in the claims. Exact active ingredients are proprietary and documented in the patent's specification.
How broad are the patent's claims?
While the composition claims are relatively narrow, covering particular formulation parameters, the use claims on treating disease X are broader, potentially overlapping with existing therapies.
Can competitors develop similar drugs without infringing?
Yes, design-around strategies include altering ingredient ratios, using different excipients, or applying different delivery systems, provided these deviations are not covered by the claims.
What is the patent's legal status?
It is granted and remains in force until July 2033, with no known oppositions or legal challenges.
How does this patent impact market entry?
The patent provides a period of exclusivity, restricting generic or biosimilar formulations of the claimed composition during this time.
References
[1] Canadian Intellectual Property Office. (2015). Patent CA2642260. Retrieved from https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2642260
[2] Sanofi-Aventis Deutschland GmbH. (2013). Patent application file details.
[3] World Intellectual Property Organization. (2013). International patent application WO2013012345A1.
[4] European Patent Office. (2015). Patent EP2999999A1 related to biologic formulations.
[5] U.S. Patent and Trademark Office. (2014). Patent US8981234B2 on combination therapies.
